TrialMultiple sclerosis (Houndmills, Basingstoke, England)2021

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.

Bruce Ac Cree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.